Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

ABSTRACT:

Background

Stratification of patients with stage III colon cancer into low (T_1-3N₁) and high (T₄ and/or N₂) risk groups is used to guide the duration of adjuvant chemotherapy. We determined the relative contribution of clinical and molecular features to survival by risk group.

Materials & methods

Stage III colon cancer (N = 5337) patients from two adjuvant trials of FOLFOX ± cetuximab [N0147 (Alliance), PETACC-8] were risk grouped, then subgrouped by clinical features and molecular variables [KRAS and BRAF/mismatch repair (MMR) combined variable]. Distributions of disease-free survival (DFS), overall survival (OS), and survival after recurrence (SAR) were estimated. In multivariable Cox models, backward elimination was performed fo

SUBMITTER: Sinicrope FA 

PROVIDER: S-EPMC7855426 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature